Hapoctasin Accord (Buprenorphine)

Hapoctasin Accord is indicated for the management of persistent, moderate‑to‑severe pain that cannot be adequately controlled with non‑opioid analgesics. It is commonly prescribed in the following clinical situations:

• Chronic severe pain associated with conditions such as osteoarthritis, neuropathy, or musculoskeletal disorders.
• Cancer‑related pain requiring continuous opioid coverage.
• Pain that is expected to persist for several days and benefits from a steady drug delivery system.
• Situations where oral administration is not feasible or reliable.
• Adjunct therapy when rotating opioids to improve analgesic response.

The safety profile of buprenorphine delivered via the Hapoctasin Accord patch includes both frequently observed and less common adverse events. Reported effects are categorized as follows:

Common

• Application site reactions such as redness, itching, or mild swelling.
• Nausea, vomiting, or constipation.
• Drowsiness or mild sedation.
• Headache or dizziness.

Serious

• Respiratory depression, especially when combined with other central nervous system depressants.
• Severe hypotension or syncope.
• Signs of opioid dependence or withdrawal upon abrupt discontinuation.

Before initiating therapy with Hapoctasin Accord, clinicians should evaluate patient‑specific factors and monitor for potential risks associated with opioid use.

• Assess for a history of respiratory disorders, such as sleep apnea or chronic obstructive pulmonary disease.
• Use caution in patients with hepatic impairment, as buprenorphine metabolism may be altered.
• Evaluate for potential drug dependence, abuse, or addiction.
• Avoid abrupt discontinuation to reduce the risk of withdrawal symptoms.
• Monitor blood pressure and heart rate regularly during treatment.
• Consider dose adjustments in elderly patients due to increased sensitivity.
• Counsel patients on proper patch application and disposal to prevent accidental exposure.

Buprenorphine can interact with several medications, influencing its analgesic effect or increasing safety concerns. Interaction categories are outlined below:

Avoid

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that can significantly reduce buprenorphine plasma levels and diminish pain control.
• Concurrent use of other opioids or central nervous system depressants (such as benzodiazepines) without careful monitoring, due to increased risk of respiratory depression.

Use with caution

• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole) which may elevate buprenorphine concentrations and require dose adjustment.
• Alcohol or medications that prolong the QT interval; combined use should be assessed for additive sedation or cardiac effects.